The Indian Contract Development and Manufacturing Organization (CDMO) sector is gaining attention as regulatory standards tighten, creating opportunities for established players. Akums Drugs & Pharmaceuticals leads the market with a 30% share in outsourced manufacturing, boasting a 51% compound annual growth rate (CAGR) in net profit. The company is expanding into regulated markets like Europe and has plans for a manufacturing plant in Lusaka, Zambia, expected to start production in 2028. Syngene International, a global CRDMO, has experienced a 3% decline in revenue due to challenges with a major client but is working to diversify its offerings and has extended its partnership with Bristol Myers Squibb through 2035. Meanwhile, Jubilant Pharmova is focusing on its CDMO segment, particularly sterile injectables, with plans for significant capital expenditures. As these companies adapt to changing regulations and market demands, their current valuations are appealing, with Akums trading at a price-to-earnings (PE) ratio of 24, Syngene at 38, and Jubilant at 29, all below their five-year averages. Investors should carefully assess these firms' long-term fundamentals and governance before making decisions.